Pending EO 12866 Regulatory Review
RIN: 0910-ZC12 | Received Date: 09/27/2024 |
Title: Considerations for Including Biopsies in Clinical Trials; Draft Guidance for Industry, Investigators, Institutions, and Institutional Review Boards | |
Agency/Subagency: HHS / FDA | Stage: Notice |
Legal Deadline: None | Section 3(f)(1) Significant: No |
International Impacts: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
Pandemic Response: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |